Intra-Cellular Therapies Inc (ITCI)
71.59
-0.45
(-0.62%)
USD |
NASDAQ |
Apr 19, 15:10
Intra-Cellular Therapies Free Cash Flow (Quarterly): -2.062M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -2.062M |
September 30, 2023 | -25.54M |
June 30, 2023 | -36.80M |
March 31, 2023 | -60.07M |
December 31, 2022 | -39.16M |
September 30, 2022 | -53.47M |
June 30, 2022 | -94.92M |
March 31, 2022 | -83.42M |
December 31, 2021 | -73.18M |
September 30, 2021 | -79.58M |
June 30, 2021 | -59.34M |
March 31, 2021 | -47.77M |
December 31, 2020 | -68.32M |
September 30, 2020 | -63.75M |
June 30, 2020 | -47.02M |
March 31, 2020 | -51.25M |
December 31, 2019 | -34.41M |
September 30, 2019 | -30.21M |
June 30, 2019 | -28.37M |
March 31, 2019 | -35.70M |
December 31, 2018 | -29.22M |
September 30, 2018 | -28.43M |
Date | Value |
---|---|
June 30, 2018 | -33.64M |
March 31, 2018 | -27.28M |
December 31, 2017 | -25.31M |
September 30, 2017 | -14.52M |
June 30, 2017 | -24.96M |
March 31, 2017 | -16.43M |
December 31, 2016 | -28.45M |
September 30, 2016 | -29.67M |
June 30, 2016 | -13.54M |
March 31, 2016 | -19.65M |
December 31, 2015 | -35.09M |
September 30, 2015 | -20.62M |
June 30, 2015 | -31.20M |
March 31, 2015 | -16.23M |
December 31, 2014 | -6.210M |
September 30, 2014 | -4.420M |
June 30, 2014 | -5.203M |
March 31, 2014 | -6.986M |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | -0.0099M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-94.92M
Minimum
Jun 2022
-2.062M
Maximum
Dec 2023
-51.51M
Average
-51.25M
Median
Mar 2020
Free Cash Flow (Quarterly) Benchmarks
Insmed Inc | -132.97M |
Fate Therapeutics Inc | -36.82M |
ADMA Biologics Inc | 16.19M |
Rhythm Pharmaceuticals Inc | -29.38M |
Amylyx Pharmaceuticals Inc | 13.20M |